Drugs interfering with blood coagulation are a mainstay of cardiovascular therapy. Despite
their widespread use, there are a number of unmet needs for current parenteral and oral …

Oral anticoagulation has been limited to vitamin K antagonists (VKAs) for over 60 years.
VKAs are effective and recommended for the prevention of venous and arterial …

The therapeutic armamentarium of parenteral anticoagulants available to clinicians is mainly
composed by unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) …

Thromboembolism involving the arterial or venous circu-lation or arising from the heart is a
common cause of morbidity and mortality. Rapidly acting parenteral anticoagulants, such as …

The limits of traditional anticoagulants, such as heparin and warfarin, have prompted the
search for new agents for prophylaxis and treatment of arterial and venous …

Thrombosis is a major contributor to the adverse outcomes associated with atherosclerotic
disease. Acute coronary syndromes (ACS) result when intravascular thrombosis occurs at …

The complexities of oral anticoagulation with warfarin have led to the search for more
practical alternative agents. Novel direct factor IIa inhibitors and direct factor Xa inhibitors …

Venous and arterial thromboembolism are a major cause for morbidity and mortality. The list
of established drugs for the prevention of thrombus formation and embolisation includes …

Until recently, vitamin K antagonists were the only available oral anticoagulants, but with
numerous limitations that prompted the introduction of new oral anticoagulants targeting the …

Anticoagulants have been used for the prevention and treatment of thrombosis for more than
40 years. During this time, numerous clinical trials have been performed and have …